The OncoDxRx-built technology's broad appeal lies in its exclusivity, huge unmet market, low operating costs, speed and utility for the majority of cancer patients. These allow it to not only prevail but dominate in an age increasingly dominated by NGS-based biomarker testing platforms.

We live in an era where precision medicine technology dominates the conversation on modern and future cancer management.

The PGA's continued success, even in a world where companion diagnostics is moving toward incorporating actionable genetic biomarkers, is due to OncoDxRx's ability to develop one-of-a-kind technologies with no or limited competition, and filling a specific, non-responder market niche without the financial and logistical complications of NGS systems.

Today, the NGS biomarker tests can only qualify 20–30% of patients for precision medicine, while leaving the majority out of reach. Complementarily, PGA assay can deliver a personalized list of top-performance cancer drugs very quickly, for those patients unresponsive to precision therapy.

OncoDxRx touts PGA as a highly flexible "All-In" technology capable of searching and mapping all 700+ approved, investigational or clinical trial cancer drugs, and identify the best performing drugs in a single run.

The PGA test is an extremely valuable asset for companies with only NGS capability to complete their test menu, to uptake much more market shares, and most importantly, to benefit more patients and to fulfill the promise of precision medicine.